According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co.

The agreement involves an At-the-Market (ATM) offering program with a maximum financing scale of up to 100 million USD. This collaboration will grant Rocket Pharmaceuticals the flexibility to issue and sell common stock to Cantor Fitzgerald at appropriate times based on market conditions. The ATM issuance mechanism allows listed companies to raise capital in batches according to funding needs, effectively optimizing the timing of financing and reducing the impact on stock prices. As a clinical-stage company focused on developing gene therapies for rare diseases, this financing arrangement will provide significant funding support for Rocket Pharmaceuticals to advance its innovative therapy development pipeline. The details of this agreement have been filed with the U.S. Securities and Exchange Commission via Form 8-K.